Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 7/20 | 0.86 |
| ▸ | ICMT | O60725 | 1/20 | 0.47 |
| ▸ | MMP2 | P08253 | 4/20 | 0.43 |
| ▸ | MMP9 | P14780 | 4/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | PTPRA | P18433 | 1/20 | 0.41 |
| ▸ | KCNT1 | Q5JUK3 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9988819 | 0.93 | SCN9A (1.00) | SCN9AICMTMMP2MMP9MAPT | |
| SCHEMBL9988894 | 0.84 | SCN9A (0.85) | SCN9AICMTMMP2MMP9MAPT | |
| SCHEMBL12070088 | 0.82 | SCN9A (0.70) | SCN9AMMP2MMP9MAPTTP53 | |
| SCHEMBL15374323 | 0.81 | SCN9A (0.68) | SCN9AMMP2MAPTTP53LMNA | |
| SCHEMBL9988856 | 0.78 | SCN9A (1.00) | SCN9AMAPTTP53LMNATHRB | |
| SCHEMBL9988849 | 0.77 | SCN9A (1.00) | SCN9AICMTMAPTTP53LMNA | |
| SCHEMBL9989820 | 0.76 | SCN9A (1.00) | SCN9AICMTMMP2MMP9MAPT | |
| SCHEMBL9988775 | 0.76 | SCN9A (0.61) | SCN9AMAPTLMNA | |
| SCHEMBL4601615 | 0.75 | SCN9A (0.60) | SCN9AMAPTTP53LMNATHRB | |
| SCHEMBL9988884 | 0.73 | SCN9A (0.59) | SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190292149-A1 | ARYL SUBSTITUTED INDOLES AND THE USE THEREOF | PURDUE PHARMA LP (US) | 2019-09-26 | — | — | US | claimed |
| US-9212139-B2 | Aryl substituted indoles and their use as blockers of sodium channels | PURDUE PHARMA, L.P. (US) | 2015-12-15 | — | — | US | claimed |
| EP-2582666-B1 | ARYL SUBSTITUTED INDOLES AND THEIR USE AS BLOCKERS OF SODIUM CHANNELS | PURDUE PHARMA LP (US) | 2014-08-13 | — | — | EP | claimed |
| US-20130296281-A1 | Aryl Substituted Indoles and Their Use as Blockers of Sodium Channels | PURDUE PHARMA L.P. (US) | 2013-11-07 | — | — | US | claimed |
| US-20190292149-A1 | ARYL SUBSTITUTED INDOLES AND THE USE THEREOF | PURDUE PHARMA LP (US) | 2019-09-26 | — | — | US | disclosed |
| US-10202344-B2 | Aryl substituted indoles and the use thereof | PURDUE PHARMA L.P. (US) | 2019-02-12 | — | — | US | disclosed |
| US-20180022699-A1 | ARYL SUBSTITUTED INDOLES AND THE USE THEREOF | PURDUE PHARMA L.P. | 2018-01-25 | — | — | US | disclosed |
| US-20180022699-A1 | ARYL SUBSTITUTED INDOLES AND THE USE THEREOF | PURDUE PHARMA L.P. | 2018-01-25 | — | — | US | disclosed |
| US-20160326111-A1 | ARYL SUBSTITUTED INDOLES AND THE USE THEREOF | PURDUE PHARMA LP (US) | 2016-11-10 | — | — | US | disclosed |
| US-20160326111-A1 | ARYL SUBSTITUTED INDOLES AND THE USE THEREOF | PURDUE PHARMA LP (US) | 2016-11-10 | — | — | US | disclosed |
| US-20160326111-A1 | ARYL SUBSTITUTED INDOLES AND THE USE THEREOF | PURDUE PHARMA LP (US) | 2016-11-10 | — | — | US | disclosed |
| US-9212139-B2 | Aryl substituted indoles and their use as blockers of sodium channels | PURDUE PHARMA, L.P. (US) | 2015-12-15 | — | — | US | disclosed |
| US-9212139-B2 | Aryl substituted indoles and their use as blockers of sodium channels | PURDUE PHARMA, L.P. (US) | 2015-12-15 | — | — | US | disclosed |
| EP-2582666-B1 | ARYL SUBSTITUTED INDOLES AND THEIR USE AS BLOCKERS OF SODIUM CHANNELS | PURDUE PHARMA LP (US) | 2014-08-13 | — | — | EP | disclosed |
| US-20130296281-A1 | Aryl Substituted Indoles and Their Use as Blockers of Sodium Channels | PURDUE PHARMA L.P. (US) | 2013-11-07 | — | — | US | disclosed |
| US-20130296281-A1 | Aryl Substituted Indoles and Their Use as Blockers of Sodium Channels | PURDUE PHARMA L.P. (US) | 2013-11-07 | — | — | US | disclosed |
| US-20130296281-A1 | Aryl Substituted Indoles and Their Use as Blockers of Sodium Channels | PURDUE PHARMA L.P. (US) | 2013-11-07 | — | — | US | disclosed |
| EP-2582666-A2 | ARYL SUBSTITUTED INDOLES AND THEIR USE AS BLOCKERS OF SODIUM CHANNELS | Purdue Pharma L.P. (US) | 2013-04-24 | — | — | EP | disclosed |
| WO-2011158108-A2 | ARYL SUBSTITUTED INDOLES AND THE USE THEREOF | PURDUE PHARMA L.P. (US) | 2011-12-22 | — | — | WO | disclosed |
| WO-2011158108-A2 | ARYL SUBSTITUTED INDOLES AND THE USE THEREOF | PURDUE PHARMA L.P. (US) | 2011-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130296281-A1 | Aryl Substituted Indoles and Their Use as Blockers of Sodium Channels | SCN5A, TRPV1, TRPV5 | SCN9A 75/4885ICMT 1456/4885MMP2 4350/4885 |
| US-20160326111-A1 | ARYL SUBSTITUTED INDOLES AND THE USE THEREOF | TRPC5, TRPV5, TRPV1 | SCN9A 110/4885ICMT 1629/4885MMP2 4263/4885 |
| US-20190292149-A1 | ARYL SUBSTITUTED INDOLES AND THE USE THEREOF | TRPC5, TRPV5, TRPV1 | SCN9A 110/4885ICMT 1629/4885MMP2 4263/4885 |
| US-20180022699-A1 | ARYL SUBSTITUTED INDOLES AND THE USE THEREOF | TRPC5, TRPV5, TRPV1 | SCN9A 110/4885ICMT 1629/4885MMP2 4263/4885 |
| US-10202344-B2 | Aryl substituted indoles and the use thereof | TRPC5, TRPV5, TRPV1 | SCN9A 110/4885ICMT 1629/4885MMP2 4263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.